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Objectives This study sought to assess the feasibility and safety of a recently described technique
of mechanical recanalization with the help of a stent-like device.
Background In the special group of acute stroke patients with an intracranial large vessel occlusion,
intravenous tissue-type plasminogen activator on its own leads to a good clinical outcome (mRS
2) in only 15% to 25% of cases. The aforementioned technique of mechanical recanalization
showed very promising clinical results.
Methods Forty patients presenting within 6 h from stroke symptom onset were enrolled. Mechani-
cal recanalization was performed using a Solitaire FR revascularization device. The primary endpoint
of the study was the clinical outcome rated with the help of the modiﬁed Rankin Scale (mRS) after
90 days.
Results Twenty-four patients (60%) showed a good clinical outcome (mRS 2) at 90 days. One
symptomatic hemorrhage was detected on follow-up computed tomography. The death rate was
12.5% (5 patients). Successful recanalization (Thrombolysis In Cerebral Infarction score 2b) of the
target vessel was achieved in 95% of the patients with a mean of 1.8 runs with the device.
Conclusions The ReFlow (Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke)
study shows that mechanical recanalization with ﬂow restoration is highly effective in stroke patients
with a large intracranial vessel occlusion presenting within 4.5 h after symptom onset. (Mechanical Re-
canalization With Flow Restoration in Acute Ischemic Stroke [ReFlow]; NCT01210729) (J Am Coll
Cardiol Intv 2013;6:386–91) © 2013 by the American College of Cardiology Foundation
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387Intravenous (IV) tissue-type plasminogen activator (tPA) is
a proven therapy to reduce morbidity and mortality for acute
ischemic stroke patients (1,2). However, in the special group
of patients presenting with an occlusion of a large intracra-
nial vessel, IV thrombolysis on its own leads to a good
clinical outcome (modified Rankin Scale [mRS]2) in only
15% to 25% of these cases compared with 40% good clinical
outcome in minor strokes (3,4). These patients are consid-
ered to be candidates for additional or primary mechanical
thrombectomy. Over the last few years, numerous recana-
lization devices have been developed, and a large number of
See page 392
prospective registries have been published (5). Until now,
we have been unaware of the clinical benefit of mechanical
recanalization in the treatment of this special group of
patients. Major points of criticism are that the primary
endpoint of all the registries was recanalization of the target
vessel, not patient outcome, although it was reported that no
randomization (IV vs. mechanical treatment) took place
(6,7).
The recently described technique of mechanical recanalization
with a stent-like device showed very promising results technically
and, more important, clinically (8,9). With this prospective study,
we aimed to assess the feasibility and safety of this method.
The ReFlow (Mechanical Recanalization With Flow
Restoration in Acute Ischemic Stroke) study is the first
prospective trial, to our knowledge, concerning mechanical
recanalization in acute ischemic stroke where the primary
endpoint is the patient’s clinical outcome, because previous
studies mainly focused on target vessel recanalization, which
does not equal good clinical outcome (10,11).
Materials and Methods
The ReFlow study was a prospective trial conducted at the
Saarland University Hospital between September 2010 and
October 2011. It was approved by the local ethics commit-
tee, and it included acute stroke patients with an intracranial
large vessel occlusion treated with mechanical recanaliza-
tion, 40 in number. All patients arriving at our institution
within the first 6 h from stroke symptom onset were
screened; those who matched the inclusion and exclusion
criteria were included in the study. The inclusion and
exclusion criteria are shown in Table 1.
Study design. For this prospective trial, 40 patients were
nrolled between September 2010 and November 2011.
he primary endpoint of the study was clinical outcome at
0 days measured with the mRS. Neurological evaluation
as performed on admission and at discharge; mRS was
ssessed by 2 experienced stroke neurologists (S.W. and
.B.) at 90 days post-treatment. Computed tomography
CT) and CT angiography were performed on admission inrder to rule out intracranial hemorrhage (ICH) and to
ssess vessel occlusions. Another CT control scan was
btained before discharge or if the patient’s symptoms
orsened. Before inclusion in the study, informed consent
as obtained either from the patient or from a legal
epresentative.
If a large vessel occlusion was found, for example,
cclusion in the M1 segment of the middle cerebral artery,
nternal carotid artery (ICA), or in the basilar artery,
reatment was started with IV tPA, provided the patients
ere eligible. Patients were then transferred for interven-
ional treatment. Depending on the patient’s neurological
tatus, they were either treated under sedation or under
eneral anesthesia with intubation and ventilation.
Optimized stroke management. Emergency services are in-
structed to bring patients with a suspected stroke directly to
the stroke treatment room in our facility, which is located
next to the CT scanner. After
neurological examination, the
native CT scan is acquired. To
reduce the time-to-treatment
decision in stroke patients after
arrival, point-of-care laboratory
analysis is performed. This has
been shown to significantly re-
duce the time-to-treatment de-
cision compared with a setup
where the laboratory workup is
performed by a centralized labo-
ratory (12). If an ICH can be
ruled out, CT angiography is
performed. Within the 4.5-h
time window, patients are
treated with IV thrombolysis di-
rectly within the CT scanner
after exclusion of clinical and
neuroradiological contraindica-
tions. If an occlusion of a large intracranial vessel is found,
the patient is transferred immediately to the angiography
suite, which is located on the same floor. Depending on the
patient’s condition, informed consent is obtained either
from the patient or from a legal representative regarding the
following interventional treatment. At this point, the deci-
sion regarding treatment under sedation or intubation and
ventilation is made, depending on the patient’s clinical
condition, such as the ability to follow commands, alertness,
and so on.
Interventional treatment. All procedures were performed on
a biplane angiography machine (Siemens Axiom Artis,
Siemens Healthcare, Munich, Germany). Mechanical re-
canalization was performed using a Solitaire FR revascular-
ization device (ev3, Irvine, California). The technique has
already been described (8,9) (Online Video 1). In patients
Abbreviations
and Acronyms
CT  computed tomography
D2D  door-to-device
ICA  internal carotid artery
ICH  intracranial
hemorrhage
IV  intravenous
MRI  magnetic resonance
imaging
mRS  modified Rankin
Scale
NIHSS  National Institutes
of Health Stroke Scale
TICI  Thrombolysis In
Cerebral Infarction
tPA  tissue-type
plasminogen activatorwith an additional atherosclerotic ICA bifurcation occlu-
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388sion, acute stenting was performed (13). If the patients
received tPA, no heparin was given according to guidelines;
the patients who were treated mechanically alone received a
bolus of 3,000 IE heparin. In the case of acute carotid
bifurcation stenting, 500 mg of IV aspirin were adminis-
tered. The angiographic outcome was rated with the Throm-
olysis In Cerebral Infarction (TICI) score, a modification of
he Thrombolysis In Myocardial Infarction (TIMI) score
dapted to the intracranial vasculature (Table 2) (14).
Post-interventional treatment. Immediately after treatment,
a control CT scan was acquired to rule out procedure-
related ICH. The patients were then transferred to the
stroke unit. A control CT was performed after 24 to 48 h or
if the patient’s symptoms worsened.
Evaluation. The primary endpoint of the study was the
clinical outcome after 90 days. Neurological evaluation was
performed on admission and at discharge; mRS was assessed
by 2 experienced stroke neurologists (S.W. and S.B.) at 90
days post-treatment. Good clinical outcome was defined as
mRS 2.
The safety endpoints were symptomatic ICH, defined as
worsening of the patient’s neurological status of more than
Table 2. TICI Score Overview
Grade 0 No perfusion
Grade 1 Perfusion past the initial obstruction but limited distal branch
ﬁlling with little or slow distal perfusion
Grade 2a Perfusion of less than half of the vascular distribution of the
occluded artery (e.g., ﬁlling and perfusion through 1 M2
division)
Grade 2b Perfusion of half or greater of the vascular distribution of the
occluded artery (e.g., ﬁlling and perfusion through 2 or
more M2 divisions)
Grade 3 Full perfusion with ﬁlling of all distal branches
Table 1. Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Age 18–85 yrs Rapidly improving neurological signs
ICA, MCA, VA, or BA
occlusion (TICI
ﬂow grade 0 or
1) within the ﬁrst
6 h from stroke
symptom onset
NHISS 30 or coma
NIHSS 10 Female patients who are pregnant or lactating
Use of warfarin anticoagulation with INR 1.5
Platelet count 30,000
Glucose 50 mg/dl
Life expectancy of 90 days
CT or MRI evidence of hemorrhage on presentation
CT showing acute ischemia on presentation
BA  basilar artery; CT  computed tomography; ICA  internal carotid artery; MCA  middle
cerebral artery; MRImagnetic resonance imaging; NIHSSNational Institutes of Health Stroke
Scale; TICI Thrombolysis In Cerebral Infarction; VA vertebral artery.TICI Thrombolysis In Cerebral Infarction.4 on the National Institutes of Health Stroke Scale (NIHSS),
and all causes of mortality at 90 days.
Secondary endpoints were recanalization of the occluded
target vessel measured by the TICI (Table 2) score of 2b or
3, door-to-device (D2D) time (time from arrival at the
hospital until the device is placed in the target lesion),
door-to-recanalization time (time from arrival at the hos-
pital until a TICI 2b or 3 state was reached), and the time
from symptom onset to recanalization.
Results
Patient population. The 40 enrolled patients were selected
rom 65 patients with acute ischemic stroke and an intra-
ranial large vessel occlusion arriving at our institution. The
xcluded patients were rejected due to unclear timeframe of
ymptom onset, use of warfarin with an international
ormalized ratio 1.5, already marked ischemia (hypoden-
ity on CT), or rapid neurological improvement. Thirteen
32.5%) patients were treated under intubation and venti-
ation due to agitation; 27 patients (67.5%) were treated
nder IV sedation.
The enrolled patients had a mean NIHSS on admission
f 16.4 with a SD of 4.1. All patients had a NIHSS score
10 on admission. The mean age was 70.1  11.8 years.
he mean time frame from symptom onset to arrival was
10 min with a SD of 59 min (minimum  29 min;
aximum  230 min). Eighty percent of the patients
rrived within 3 h from symptom onset; the remaining 20%
rrived within the first 4.5 h. Twelve patients were treated
ithout IV tPA due to contraindications; the others re-
eived a standard 10% bolus of the maximum dose (0.9
g/kg body weight). IV tPA was halted on accession of the
arget vessel; no additional IA (intra-arterial) tPA was
iven. All patients had a TICI score of 0 on admission.
wenty-eight patients had an M1/M2 occlusion; 10 had an
cclusion of the terminal ICA; and 2 patients were treated
or basilar artery occlusion. Six patients had to be treated for
cute ICA bifurcation occlusion first. Table 3 provides an
Table 3. Baseline Characteristics
Age, yrs 70.1  11.8
Men 19 (47.5)
Current or former smoker 16 (40)
Cardioembolic cause of stroke 22 (55)
Baseline NIHSS 16.4  4.1
Time from symptom onset to arrival, min 110  59
Patients under 3 h from symptom onset to CT 32 (80)
Hypertension 16 (40)
Diabetes 7 (17.5)
Values are mean SD or n (%).
Abbreviations as in Table 1.overview of the patients’ baseline characteristics.
s
p
o
e
C
t
i
p
(

p
(
t
n
d
w
c
D
Scale
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 4 , 2 0 1 3 Roth et al.
A P R I L 2 0 1 3 : 3 8 6 – 9 1 The ReFlow Study
389Clinical outcome. Good clinical outcome (mRS 2) was
een in 24 patients (60%) at 90 days. In this subgroup, 8
atients showed a mRS of 0, and 8 presented with a mRS
f 1. Figure 1 provides a detailed overview of the primary
ndpoint.
One symptomatic hemorrhage was detected on follow-up
T; symptomatic was defined as worsening of 4 points on
he NIHSS. Three hemorrhagic transformations of the
nfarct core were also seen without worsening of the
atient’s neurological status. The death rate was 12.5%
n  5) (Table 4).
Angiographic outcome. Successful recanalization (TICI
2b) of the target vessel was achieved in 95% of the
atients, with a mean of 1.8 runs with the device. In 12 cases
30%), a purely mechanical approach was used. In all of
hese patients, a TICI score of 3 was achieved. There were
o visible vessel perforations with the microwire and no
issections. In 1 case, mild vasospasm in the target vessel
as observed. Table 5 provides an overview of the interven-
tional results.
The mean time from arrival of the patient until placement
of the device and temporary re-establishment of flow (D2D
time) was 96 min. With the optimized stroke treatment, a
D2D time of 100 min was achieved in 67.5% of patients.
Figure 1. Clinical Outcome at 90 Days
Clinical outcome of the patients at 90 days evaluated by the modiﬁed Rankin
Table 4. Clinical Results
10-point improvement on NIHSS at 24 h 18 (45)
mRS 2 at 90 days 24 (60)
IV lysis, mg 38.1  32.4
Intubation and ventilation 13 (32.5)
Symptomatic ICH 1 (2.5)
Death rate 5 (12.5)
Values are n (%) or mean SD.
ICH  intracranial hemorrhage; IV  intravenous; mRS  modified Rankin Scale; NIHSS National Institutes of Health Stroke Scale.Patients with a D2D time of 100 min had a favorable
outcome in 66% of cases, compared with 44% in patients
with a D2D time of more than 100 min (Fig. 2). Table 6
shows the various recorded times from symptom onset to
recanalization, and Table 7 shows correlations between
linical outcome and various parameters.
iscussion
This prospective study demonstrates the efficacy and
safety of mechanical recanalization with flow restoration
in patients with a large intracranial vessel occlusion in
combination with a substantial neurological deficit. The
main findings are a high rate of favorable clinical out-
come at 3 months (60%), a low rate of symptomatic
hemorrhage (2.5%), and a low rate of mortality (12.5%).
Because all the patients presented within the first 4.5 h,
the results can only apply to patients presenting within
this time window.
(mRS).
Table 5. Results of the Intervention
MCA occlusion 28 (70)
BA occlusion 2 (5)
Terminal ICA occlusion 10 (25)
Acute stenting of ICA bifurcation 6 (15)
TICI 2b 38 (95)
Solitaire runs, mean (maximum) 1.8 (5)
Vasospasm 1 (2.5)
Periprocedural complications 0
Pure mechanical treatment 12 (30)
IA lysis, mg 0
Thrombus harvested 39 (97.5)
Values are n (%) or n.IA intra-arterial; other abbreviations as in Table 1.
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390The favorable clinical outcome is higher in comparison to
previous studies using flow restoration devices (45% to 50%)
(9,15). This may reflect the fact that in this study, there was
a higher rate of patients who presented within the first 3 h
after symptom onset, the increased experience of the inter-
ventionalists with this technique, and the optimization of
stroke treatment (12). Furthermore, no patients beyond 6 h
from stroke symptom onset were included in the study, and
the treatment was started immediately after diagnosis. The
clinical improvement observed in the present study is higher
in comparison to the clinical outcome reported in other
prospective studies in which mechanical thrombectomy
devices were used. In the MERCI (Mechanical Embolus
Removal in Cerebral Ischemia) trial, the functional outcome
of an mRS of 2 was achieved in only 28% of the patients
(36% in the Multi MERCI [Mechanical Embolus Removal
in Cerebral Ischemia (MERCI™)] trial) (11). The Penum-
bra Pivotal Stroke trial showed an outcome of mRS 2 in
only 25% (10). In our opinion, the improved clinical
outcome with flow restoration devices is due to fast and
effective clot removal, and the possibility of temporarily
Figure 2. Correlation Between D2D Time and Clinical Outcome
Correlation between D2D time and clinical outcome. Patients with a D2D
time of 100 min had a favorable outcome (mRS 2) in 66% of cases,
compared with 44% in patients with a D2D time of more than 100 min.
D2D  door-to-device; mRS  modiﬁed Rankin Scale.
Table 6. Overview of the Various Times
Symptom onset to recanalization, min 208 69
Time from CT to angiography, min 43 22
Intervention time, min 54 40
D2D, min 96 33
Door-to-recanalization, min 113 38
Values are mean SD.CT computed tomography; D2D door-to-device.restoring flow between retrieval attempts, a feature that is
impossible with the devices used in the MERCI, Multi
MERCI, and Penumbra trials.
The rate of symptomatic ICH (2.5%) and the mortality rate
(12.5%) are significantly lower compared with previous pro-
spective studies using mechanical thrombectomy. Symptom-
atic intracranial hemorrhage was reported in 10% of patients
with the MERCI Retriever, and in 11% with the Penumbra
system. The mortality rates in the MERCI and Penumbra
trials ranged from 32.5% to 44% (10,11). The low rate of
mortality (12.5%) in our study reflects the low rate of symp-
tomatic ICH and shows the safety of flow restoration devices
compared with the MERCI device and the Penumbra system.
The high recanalization rate (95%) in our study is
comparable with the recanalization rate of retrospective
studies using the Solitaire FR device (9,15). The MERCI
and Penumbra trials reported rates of successful recanaliza-
tion from 43% to 78%. However, recanalization success was
typically defined as a TIMI flow grade of 2 (partial) or 3
(complete) within the target vessel on angiography after the
procedure, without paying attention to the distal vessel
territories. Because the TICI score includes the recanaliza-
tion state of distal branches, we estimate that the recanali-
zation rates of the MERCI and Penumbra trials would have
been even lower if rated with the TICI score. This confirms
that flow restoration devices (stent retrievers) and especially
the Solitaire FR are highly effective for thrombus removal
and recanalization of the entire affected vasculature.
Another important finding of our study is that with the
use of optimized stroke management, a D2D time (time
from arrival at the hospital until the device is placed in the
target vessel) of 100 min can be achieved in almost
two-thirds of the patients. Patients with a D2D time of
100 min had a favorable outcome in 66% of patients,
compared with 44% of patients with a D2D time of more
than 100 min. This finding was not statically significant due
Table 7. Correlation Between Clinical Outcome and Various Parameters
Favorable
Clinical Outcome
(n  24)
Unfavorable
Clinical Outcome
(n  16) p Value
Age, yrs 67.52  12.91 74  8.8 0.1 (NS)
Initial NIHSS 15.21  3.97 18.13  3.86 0.05
Atrial ﬁbrillation 11 (45.8) 11 (68.75) 0.1 (NS)
Hypertension 17 (70.8) 13 (81.25) 0.1 (NS)
Former/current smoker 13 (54.2) 3 (18.7) 0.1 (NS)
Intubation 8 (33) 4 (25) 0.1 (NS)
IV lysis 17 (70.8) 11 (68.8) 0.1 (NS)
D2D, min 91.79  31.55 102.1  35.0 0.1 (NS)
Symptom onset to
recanalization, min
213.50  81.67 199.63  45.15 0.1 (NS)
Values are mean SD or n (%).
Abbreviations as in Table 4 and 6.to the small sample size. However, it is to be expected that
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391by analogy with the influence of the door-to-balloon time in
the outcome of patients with ST-segment elevation myo-
cardial infarction, the D2D time might also play an impor-
tant role in the outcome of these patients (16,17). Despite
the fact that the efficacy of IV thrombolysis decreases with
time, due to in-hospital delays, less than one-third of
patients meet the goal of a “door-to-needle time” of 60 min
or less (18). Improvements in pre-hospital and in-hospital
stroke management can translate into increased eligibility
for thrombolysis and prompter treatment (19,20). Our
optimized stroke management includes point-of-care labo-
ratory testing instead of testing by the centralized hospital
laboratory—a change that achieved important time savings
in stroke management (12). Our data suggest that physi-
cians, hospitals, and healthcare systems should work to
reduce the “door-to-device” time, as has been done for
“door-to-balloon” time in ST-segment elevation myocardial
infarction patients by the American Heart Association
(21–23). Moreover, we suggest that in randomized trials for
comparison of mechanical thrombectomy to IV thrombol-
ysis, a limit should be defined for D2D time.
Study limitations. All patients presented within the first 4.5 h
fter symptom onset, so the results can only apply to patients
resenting within this time window, which makes the study
lightly less comparable to previous studies that included
atients up to 8 h from symptom onset. Another limitation is
he lack of a control group (patients treated with IV throm-
olysis on its own) with which to compare the results.
onclusions
The ReFlow study shows that mechanical recanalization
with flow restoration is highly effective in patients present-
ing within 4.5 h after symptom onset. To confirm these
results, there is no doubt that a randomized trial is needed
to compare mechanical recanalization plus IV thrombolysis
with IV thrombolysis on its own. Our study demonstrates
that in such a trial, a flow restoration device should be used
for mechanical thrombectomy, and optimized in-hospital
stroke management in which a limit of D2D time should be
defined.
Reprint requests and correspondence: Dr. Panagiotis Papanag-
iotou, Clinic for Diagnostic and Interventional Neuroradiology,
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